Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
Anosmia
Autoimmune encephalitis
Limbic system
Neuroinflammation
Smell impairment
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
08
10
2021
accepted:
31
12
2021
revised:
31
12
2021
pubmed:
11
1
2022
medline:
23
4
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Despite being long neglected, olfaction has recently become a focus of intense research in neuroscience, as smell impairment has been consistently documented in both neurodegenerative and neuroinflammatory diseases. Considering the close anatomo-functional correlations between the limbic system and the central olfactory structures, we investigated olfaction in a population of patients with autoimmune encephalitis (AE). Nineteen adult subjects (14 males, median age 64 years) diagnosed with definite (14/19) or possible (5/19) AE and followed for ≥ 6 months were enrolled. The Brief Smell Identification Test (B-SIT), a 12-item, forced-choice, scratch-and-sniff measure, was used to assess the patients' olfactory function in comparison with a group of sex- and age-matched healthy controls (HC). According to the B-SIT score, subjects were classified as anosmic (< 6), hyposmic (6-8) and normal (≥ 9). Electro-clinical, laboratory and neuroimaging findings were reviewed. Smell impairment was revealed in 15/19 patients (9 hyposmic, 6 anosmic), compared with 5/19 HC (p = 0.0029). Age, gender and smoking habits did not affect the participants' performance at B-SIT. Olfactory dysfunction appeared more common among patients with definite AE (p = 0.0374), regardless of autoantibody status. Subjects with higher modified Rankin Scale (mRS) scores at AE onset more likely presented hyposmia/anosmia (p = 0.033), and so did those with bilateral ictal/interictal EEG abnormalities (p = 0.006). We found olfaction to be impaired in a significantly large proportion of AE cases. Smell deficits appeared more common in subjects with severe AE (as indicated by both definite diagnosis and higher mRS score), and might represent an additional feature of immune-mediated encephalitis.
Sections du résumé
BACKGROUND
BACKGROUND
Despite being long neglected, olfaction has recently become a focus of intense research in neuroscience, as smell impairment has been consistently documented in both neurodegenerative and neuroinflammatory diseases. Considering the close anatomo-functional correlations between the limbic system and the central olfactory structures, we investigated olfaction in a population of patients with autoimmune encephalitis (AE).
METHODS
METHODS
Nineteen adult subjects (14 males, median age 64 years) diagnosed with definite (14/19) or possible (5/19) AE and followed for ≥ 6 months were enrolled. The Brief Smell Identification Test (B-SIT), a 12-item, forced-choice, scratch-and-sniff measure, was used to assess the patients' olfactory function in comparison with a group of sex- and age-matched healthy controls (HC). According to the B-SIT score, subjects were classified as anosmic (< 6), hyposmic (6-8) and normal (≥ 9). Electro-clinical, laboratory and neuroimaging findings were reviewed.
RESULTS
RESULTS
Smell impairment was revealed in 15/19 patients (9 hyposmic, 6 anosmic), compared with 5/19 HC (p = 0.0029). Age, gender and smoking habits did not affect the participants' performance at B-SIT. Olfactory dysfunction appeared more common among patients with definite AE (p = 0.0374), regardless of autoantibody status. Subjects with higher modified Rankin Scale (mRS) scores at AE onset more likely presented hyposmia/anosmia (p = 0.033), and so did those with bilateral ictal/interictal EEG abnormalities (p = 0.006).
CONCLUSIONS
CONCLUSIONS
We found olfaction to be impaired in a significantly large proportion of AE cases. Smell deficits appeared more common in subjects with severe AE (as indicated by both definite diagnosis and higher mRS score), and might represent an additional feature of immune-mediated encephalitis.
Identifiants
pubmed: 35006386
doi: 10.1007/s00415-022-10959-6
pii: 10.1007/s00415-022-10959-6
pmc: PMC8743233
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2762-2768Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Science. 1984 Dec 21;226(4681):1441-3
pubmed: 6505700
Seizure. 2019 Jul;69:204-206
pubmed: 31082694
J Clin Neurosci. 2015 Oct;22(10):1614-8
pubmed: 26149406
Seizure. 2020 Dec;83:160-168
pubmed: 33161244
Mol Neurobiol. 2019 May;56(5):3714-3721
pubmed: 30191380
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Chem Senses. 2012 May;37(4):325-34
pubmed: 22045704
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
JAMA. 2002 Nov 13;288(18):2307-12
pubmed: 12425708
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Curr Otorhinolaryngol Rep. 2016 May;4(2):130-141
pubmed: 30613439
Neurology. 2019 Feb 12;92(7):e700-e709
pubmed: 30651382
Brain. 2021 Oct 22;144(9):2709-2721
pubmed: 33843981
Front Neurol. 2019 May 14;10:480
pubmed: 31156532
J Neurol. 2018 Jul;265(7):1654-1665
pubmed: 29767353
Lancet Neurol. 2017 Jun;16(6):478-488
pubmed: 28504111
Am J Phys Anthropol. 2010;143 Suppl 51:63-74
pubmed: 21086527
J Neurol. 2008 Aug;255(8):1121-6
pubmed: 18677645